ClinicalTrials.gg
RecruitingNCT05285839Updated Mar 15, 2024

Dupixent and Narrowband UVB for Atopic Dermatitis

A Phase 4 interventional study of Dupixent in Atopic Dermatitis, sponsored by Psoriasis Treatment Center of Central New Jersey. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-03-15.

Sponsored by Psoriasis Treatment Center of Central New Jersey · Phase 4, Interventional, and Treatment

How we know · 3 judgments

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 11 months ago, but the record still lists the study as recruiting.
  • Started Apr 2022; still recruiting 4 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 639 studies in Dermatitis, Atopic with a site in United States — 78 open to participants now, 117 under way, 18 of them phase 3. Dermatitis, Atopic · United States.

Planned enrollment
369th of 544
40 · median 96
Started
2022
with 44 others
Phase 4
70 of 639
11 open now
Primary completion
2024-12
later than 3 of 115 live
Registered
457th of 639
by date

Among the 639 studies in Dermatitis, Atopic with a site in United States, this one is the 369th largest by planned enrollment of the 544 interventional ones that give a count, is one of 45 that started in 2022, is one of 70 in phase 4, reaches primary completion later than 3 of the 115 other live ones, and was the 457th registered.

Dermatitis, Atopic

1,596 studies on the registry are indexed under Dermatitis, Atopic; 289 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

78 of the 639 studies in Dermatitis, Atopic with a site in United States are open now. Recruiting first, the newest first:

73 more — sign in →

All 78 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 195 Dermatitis, Atopic studies recruiting now, 84 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 52 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 639 studies in Dermatitis, Atopic with a site in United States, or all of them as a file.
02

Study summary

24 weeks open-label study with dupilumab and narrowband UVB phototherapy three times weekly for 12 weeks followed by 12 weeks of dupilumab monotherapy.

Read the detailed description

24 weeks open-label study with dupilumab and narrowband UVB phototherapy three times weekly for 12 weeks followed by 12 weeks of dupilumab monotherapy.

03

Conditions studied

  • Atopic Dermatitis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female adult ≥ 18 years of age;
  • Diagnosis of moderate to severe atopic dermatitis as defined at baseline by:

    • EASI score of 16 or greater,
    • IGA score of 3 or greater
    • BSA of 10% or greater,

Exclusion criteria

Exclusion Criteria:

  • Subjects with previous exposure to dupilumab.
  • Known or suspected to dupilumab or any of its .
  • History of photosensitivity.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Dupixent and Narrowband UVB

    Dupixent and Narrowband UVB

    Drug: Dupixent

Interventions

06

What researchers measure

Primary outcomes

  1. Investigators Global Assessment Score of score of 0 or 1

    Proportion of subjects achieving an IGA score of 0 or 1 with at least a 2 grade improvement at week 12

    Time frame: 12 weeks

07

Study locations

1 of 1 sites recruiting
  • Eczema Treatment Center of New Jersey
    East Windsor, New Jersey 08520, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2022 (actual). Primary completion is estimated for Dec 2024, 31 months after the start.

Of 45 phase 4 interventional studies under Dermatitis, Atopic, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 41. This study's planned 31 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 8, 2022
First posted
Mar 18, 2022
StartActual
Apr 19, 2022
Primary completionEst.
Dec 1, 2024
CompletionEst.
Dec 15, 2024
Last update
Mar 15, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 15, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05285839
Lead sponsor
Psoriasis Treatment Center of Central New Jersey
Responsible party
Sponsor
First posted
Mar 18, 2022
Start date
Apr 19, 2022
Primary completion
Dec 1, 2024 (estimated)
Completion
Dec 15, 2024 (estimated)
Last update
Mar 15, 2024

Study contacts

Elise Nelson
Contact
enelson@windsordermatology.com
6094434500

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion